Page last updated: 2024-11-01

nimodipine and Cancer of Prostate

nimodipine has been researched along with Cancer of Prostate in 2 studies

Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Perret, S1
Cantereau, A1
Audin, J1
Dufy, B1
Georgescauld, D1
Jan, CR1
Jiann, BP1
Lu, YC1
Chang, HT1
Su, W1
Chen, WC1
Yu, CC1
Huang, JK1

Other Studies

2 other studies available for nimodipine and Cancer of Prostate

ArticleYear
Interplay between Ca2+ release and Ca2+ influx underlies localized hyperpolarization-induced [Ca2+]i waves in prostatic cells.
    Cell calcium, 1999, Volume: 25, Issue:4

    Topics: Calcium; Calcium Channel Blockers; Calcium Signaling; Cell Polarity; Electric Stimulation; Enzyme In

1999
Effect of the organotin compound triethyltin on Ca2+ handling in human prostate cancer cells.
    Life sciences, 2002, Feb-01, Volume: 70, Issue:11

    Topics: Calcium; Calcium-Transporting ATPases; Dose-Response Relationship, Drug; Drug Antagonism; Fura-2; Hu

2002